Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer

Abstract

We found that hepatitis B X-interacting protein (HBXIP) was able to activate the CD147 promoter through Sp1. In vivo, depletion of HBXIP decreased the tumor volume and weight induced by CP. Taken together, these results indicate that HBXIP promotes cisplatin resistance and regulated CD147 via Sp1 in ovarian cancer cell lines. AbstractOvarian cancer is the highest mortality rate of all female reproductive malignancies. Drug resistance is a major cause of treatment failure in malignant tumors. Hepatitis B X-interacting protein acts as an oncoprotein, regulates cell proliferation, and migration in breast cancer. We aimed to investigate the effects and mechanisms of hepatitis B X-interacting protein on resistance to cisplatin in human ovarian cancer cell lines. The mRNA and protein levels of hepatitis B X-interacting protein were detected using RT-PCR and Western blotting in cisplatin-resistant and cisplatin-sensitive tissues, cisplatin-resistant cell lines A2780/CP and SKOV3/CP, and cisplatin-sensitive cell lines A2780 and SKOV3. Cell viability and apoptosis were measured to evaluate cellular sensitivity to cisplatin in A2780/CP cells. Luciferase reporter gene assay was used to determine the relationship between hepatitis B X-interacting protein and CD147. The in vivo function of hepatitis B X-interacting protein on tumor burden was assessed in cisplatin-resistant xenograft models. The results showed that hepatitis B X-interacting protein was highly expressed in ovarian cancer of cisplatin-resistant tissues and cells. Notably, knockdown of hepatitis B X-interacting protein significantly reduced cell viability in A2780/CP compared with cisplatin treatment alone. Hepatitis B X-interacting protein and cisplatin cooperated to induce apoptosis and increase the expression of c-caspase 3 as well as the Bax/Bcl-2 ratio. We confirmed that hepatitis B X-interacting protein up-regulated CD147 at the protein expression and transcriptional levels. Moreover, we found that hepatitis B X-interacting protein was able to activate the CD147 promoter through Sp1. In vivo, depletion of hepatitis B X-interacting protein decreased the tumor volume and weight induced by cisplatin. Taken together, these results indicate that hepatitis B X-interacting protein promotes cisplatin resistance and regulated CD147 via Sp1 in ovarian cancer cell lines.

Molecular Mechanisms Involved in Oxidative Stress-Associated Liver Injury Induced by Chinese Herbal Medicine: An Experimental Evidence-Based Literature Review and Network Pharmacology Study

“…Interestingly, in addition to being the downstream substrate of caspase-3, Bcl-2, with its antiapoptotic property, can be inactivated by caspase-3 and converted into a pro-apoptosis motivator unrelated to Bax/Bcl-2 pathway, suggesting that a feedback loop between Bcl-2 and caspase-3 exists [ 156 ]. Considerable evidence supports the idea that enhanced Bax/Bcl-2 ratio, combined with cleavage of caspase-3, takes place in various liver diseases, including chronic hepatitis, alcoholic liver, and hepatocellular carcinoma (HCC) [ 157 , 158 , 159 ].…”

Psychological Stress Up-Regulates CD147 Expression Through Beta-Arrestin1/ERK to Promote Proliferation and Invasiveness of Glioma Cells

“…In recent years, important progress on the regulation of beta receptors in different pathological processes has been reported. For example, a study on beta-arrestin1 knockout mice revealed that under chronic stress, DNA damage and genomic instability resulted from the β-AR-beta-arrestin1 pathway ( 12 ). Our study found that CD147 was up-regulated by β-AR under NE stimulation, but no obvious increase in MCT1 and MCT4 was observed, this result is not shown in the article.…”

“…CD147 (also known as extracellular matrix metalloproteinase inducer, EMMPRIN) is widely expressed on the surface of a variety of tumor cells (10,11). Importantly, CD147 can stimulate fibroblasts to produce diverse matrix metalloproteinases (MMPs) (12,13). But it also can stimulate tumor cells to produce MMPs, specifically MMP-2 and MMP-9.…”

Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses

“…GeneMANIA results indicated that MMP1 was closely associated with 20 genes, including BSG, TRIP6, ITGA2, F2R, MMP3, COPS5, etc. And four genes (ITGA2, BSG, TRIP6, and COPS5) have been found to regulate drug resistance in different cancer models [ 56 – 59 ]. Especially, COPS5 was significantly upregulated in the erlotinib resistance dataset GSE80344 and NSCLC tissues.…”